Clinical application of recombinant human thyroid-stimulating hormone in management of differentiated thyroid carcinoma.
- Author:
Bin LIU
1
;
Anren KUANG
Author Information
1. Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Iodine Radioisotopes;
therapeutic use;
Thyroglobulin;
blood;
Thyroid Hormones;
administration & dosage;
Thyroid Neoplasms;
blood;
drug therapy;
radiotherapy;
Thyrotropin Alfa;
administration & dosage
- From:
Journal of Biomedical Engineering
2012;29(3):588-592
- CountryChina
- Language:Chinese
-
Abstract:
Traditionally, during the follow-up and in order to receive 131 I therapy, patients with differentiated thyroid carcinoma (DTC) have to withdraw from using thyroid hormone. The hypothyroidism induced by hormone withdrawal can negatively affect the quality-of-life (QOL) of DTC patients. Without the hormone withdrawal, recombinant human thyroid-stimulating hormone-aided management of DTC patients can effectively obviate the consequences of hypothyroidism. This review will focus on the clinical application of recombinant human thyroid-stimulating hormone (rhTSH) in the management of DTC patients.
